These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29956640)

  • 21. Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect?
    Kwee SA; Lim J; Coel MN
    Clin Nucl Med; 2017 Nov; 42(11):868-871. PubMed ID: 28872544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline
    García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
    Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
    Blacksburg SR; Witten MR; Haas JA
    Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
    Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
    Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen flare induced by
    Castello A; Macapinlac HA; Lopci E; Santos EB
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.
    Keizman D; Fosboel MO; Reichegger H; Peer A; Rosenbaum E; Desax MC; Neiman V; Petersen PM; Mueller J; Cathomas R; Gottfried M; Dresler H; Sarid D; Mermershtain W; Rouvinov K; Mortensen J; Gillessen S; Daugaard G; Omlin A
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):289-293. PubMed ID: 28244493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of Palliative
    Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T
    J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative Assessment of Early [
    Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
    J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
    Wale DJ; Viglianti BL; Gross MD; Ferretti A; Rubello D; Wong KK
    Am J Clin Oncol; 2019 Jan; 42(1):99-106. PubMed ID: 30204613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radium-223 dichloride in clinical practice: a review.
    Florimonte L; Dellavedova L; Maffioli LS
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
    Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.
    Rohren EM; Etchebehere EC; Araujo JC; Hobbs BP; Swanston NM; Everding M; Moody T; Macapinlac HA
    J Nucl Med; 2015 Oct; 56(10):1507-12. PubMed ID: 26135112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?
    García Vicente AM; Soriano Castrejón Á; Alvarez Cabellos R; Sanchez Gil B; Mohedano Mohedano N
    Clin Nucl Med; 2017 Oct; 42(10):761-765. PubMed ID: 28806246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fatal Intracranial Hemorrhage Due to Thrombocytopenia in a Patient With Castration-Resistant Prostate Cancer Showing Extensive Bone Uptake of Injected 223Ra Dichloride.
    Nakahara T; Owaki Y; Kosaka T; Fukada J; Ichimura A; Jinzaki M
    Clin Nucl Med; 2018 Jul; 43(7):546-547. PubMed ID: 29742607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
    Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN
    Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning.
    Ahmadzadehfar H; Essler M; Rahbar K; Afshar-Oromieh A
    PET Clin; 2018 Oct; 13(4):491-503. PubMed ID: 30219184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.
    Vidal M; Delgado A; Martinez C; Correa JJ; Durango IC
    Int Braz J Urol; 2020; 46(4):599-611. PubMed ID: 32213206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
    Vija Racaru L; Sinigaglia M; Kanoun S; Ben Bouallègue F; Tal I; Brillouet S; Bauriaud-Mallet M; Zerdoud S; Dierickx L; Vallot D; Caselles O; Gabiache E; Pascal P; Courbon F
    Nucl Med Commun; 2018 Jul; 39(7):672-679. PubMed ID: 29790867
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Boni G; Mazzarri S; Cianci C; Galli L; Farnesi A; Borsatti E; Bortolus R; Fratino L; Gobitti C; Lamaj E; Ghedini P; Rizzini EL; Massari F; Dionisi V; Fanti S; Volterrani D; Monari F
    Tumori; 2018; 104(2):128-136. PubMed ID: 29714668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
    Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
    Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.